PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China

Abstract Background Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complet...

Full description

Bibliographic Details

Published in:	World Journal of Surgical Oncology
Main Authors:	Xiaoyu Liu, Zhaoyun Liu, Chao Li, Xiang Song, Xinzhao Wang, Sumei Li, Zhiyong Yu
Format:	Article
Language:	English
Published:	BMC 2023-09-01
Subjects:	HER2-positive breast cancer Progesterone receptor Neoadjuvant therapy Pathological complete response
Online Access:	https://doi.org/10.1186/s12957-023-03178-4